Monday, April 03, 2017 12:17:47 PM
http://www.otcmarkets.com/stock/GBLX/news/GB-Sciences-Submits-Offer-to-Louisiana-State-University--LSU--for-Providing-the-Cultivation--Extraction--Processing-and-Production-of-Medical-Cannabis-Pursuant-to-the-Alison-Neustrom-Act?id=154931
PR Newswire
LAS VEGAS, April 3, 2017
LAS VEGAS, April 3, 2017 /PRNewswire/ -- GB Sciences, Inc. (formerly known as Growblox Sciences, Inc.) (OTCQB: GBLX) submits offer to Louisiana State University (LSU) to act as the LSU licensed operator of their medical cannabis production facility as outlined in the Alison Neustrom Act (hereinafter referred to as the "Act"). The offer would enable GB Sciences to be the sole vendor of cannabis and extracted cannabis compounds on behalf of LSU for the patients of Louisiana. LSU and Southern University have the only two licenses granted by the State of Louisiana to cultivate, distribute, and sell medical cannabis.
The Act specifically authorizes the LSU AgCenter to conduct research on medical cannabis. The AgCenter will operate a separate research division for independent research. The research division may operate alongside and in the same facility as the Production Entity's commercial operation, which will produce therapeutic medical cannabis products for qualified patients of Louisiana. If GB Sciences is selected to work with LSU, it will have first rights to commercialize any inventions or discovery of research center. GB Sciences is looking forward to the prospect of working with LSU on GB Sciences' cannabis tissue propagation technology.
The facility will serve the approximate five million people who live in the state of Louisiana. The cultivation plant will contain a minimum of a 5,000 square foot research lab.
In order to fulfill the requirements of the application, GB Sciences is raising two million dollars in bonds. The bonds will collateralize a required bid bond associated with the offer to LSU. This is an open bid process with only a few offers due to the one million dollar bid bond provision. The license and partnership is for the development of new cannabis based medical compounds and tissue propagation development for new cannabis drug discovery to advance the GB Sciences (GBLX) patented formulations toward FDA approved Clinical Trials.
Recent GBLX News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/12/2024 09:39:05 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 10:07:34 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 10/10/2023 02:00:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/08/2023 08:15:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 06:31:48 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 08/02/2023 08:18:58 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 07/14/2023 08:12:47 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 06/30/2023 12:00:24 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM